Antiproliferative and cell apoptosis-inducing activities of compounds from Buddleja davidii in Mgc-803 cells by Jian Wu et al.
Wu et al. Cell Division 2012, 7:20
http://www.celldiv.com/content/7/1/20RESEARCH Open AccessAntiproliferative and cell apoptosis-inducing
activities of compounds from Buddleja davidii in
Mgc-803 cells
Jian Wu†, Wenshi Yi†, Linhong Jin, Deyu Hu and Baoan Song*Abstract
Background: Buddleja davidii is widely distributed in the southwestern region of China. We have undertaken a
systematic analysis of B. davidii as a Chinese traditional medicine with anticancer activity by isolating natural
products for their activity against the human gastric cancer cell line Mgc-803 and the human breast cancer cell line
Bcap-37.
Results: Ten compounds were extracted and isolated from B. davidii, among which colchicine was identified in
B. davidii for the first time. The inhibitory activities of these compounds were investigated in Mgc-803, Bcap-37 cells
in vitro by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, and the results showed that
luteolin and colchicine had potent inhibitory activities against the growth of Mgc-803 cells. Subsequent
fluorescence staining and flow cytometry analysis indicated that these two compounds could induce apoptosis in
Mgc-803 cells. The results also showed that the percentages of early apoptotic cells (Annexin V+/PI-, where PI is
propidium iodide) and late apoptotic cells (Annexin V+/PI+) increased in a dose- and time-dependent manner.
After 36 h of incubation with luteolin at 20 μM, the percentages of cells were approximately 15.4% in early
apoptosis and 43.7% in late apoptosis; after 36 h of incubation with colchicine at 20 μM, the corresponding values
were 7.7% and 35.2%, respectively.
Conclusions: Colchicine and luteolin from B. davidii have potential applications as adjuvant therapies for treating
human carcinoma cells. These compounds could also induce apoptosis in tumor cells.
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Buddleja belongs to the Loganiaceae family and has a pan-
tropical distribution across South Asia, Africa, and Amer-
ica [1]. This genus comprises approximately 100 species of
wood perennials and shrubs. The roots, leaves, and flowers
of various species of Buddleja are used in folk medicine in
several parts of the world [2]. Various bioactivities, includ-
ing antimicrobial activity against Staphylococcus aureus, as
well as antihepatotoxic, antirheumatic, antiprotozoal, and
antifungal properties of isolated compounds from Bud-
dleja have been reported [3-10]. The application of the* Correspondence: songbaoan22@yahoo.com
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reproduction in any medium, provided the orpoultice or lotion of a number of species of Buddleja to
treat wounds has also been documented [11,12].
Buddleja davidii is a perennial herbaceous plant
widely distributed in the Chinese provinces of Yunnan,
Guizhou, Sichuan, and Xizang. In Chinese folk medicine,
the roots, leaves, and stems of this plant are consumed
by drinking an infusion with alcoholic content for the
treatment of rheumatism, cough, and fractures.
Studies have evaluated crude extract and different ex-
tract partitions from Buddleja for their free radical scav-
enger capacity; neural tissue protection [13]; as well as
anticonvulsant [14], antioxidant [15], anti-plasmodium
[16], antiviral [17], anti-inflammatory [18,19], and anti-
fungal [9] activities. To the best of our knowledge, the
anticancer activity of B. davidii has not been studied yet.
The aim of this study was to investigate the anticancer
property of isolated compounds of B. davidii.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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davidii grown in Guizhou and identified by spectro-
scopic and physicochemical analysis: luteolin 1, narin-
genin 2, puerarin 3, rutin 4, quercetin 5, hesperetin 6,
and acacetin-7-O-α-L-rhamno- pyranosyl(1–6)-β-D-glu-
copyranoside 7 (flavonoids); stigmasterol 8 (steroid);
ferulic acid 9 (phenylpropanoid); and colchicine 10 ( al-
kaloid ). Colchicine 10 was extracted from B. davidii for
the first time. All compounds were subjected to bioassay
against the human gastric cancer cell line Mgc-803 and
the human breast cancer cell line Bcap-37 in vitro using
the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] method. Luteolin had more potent in-
hibitory activities against the growth of Mgc-803 cells
than the other compounds, and colchicine exhibited
high activities against the growth of these cells as well.
Further investigations of luteolin and colchicine were
thus carried out in Mgc-803 and Bcap-37 cells. Their
IC50 values were determined. Fluorescent staining and
flow cytometry analysis indicated that both compounds
could induce apoptosis in Mgc-803 cells. To the best of
our knowledge, this is the first study to report on the
apoptosis-inducing and antitumor activities of luteolin
and colchicine in Mgc-803 and Bcap-37 cells.
Results and discussion
Chemistry
Dried B. davidii samples collected from Guizhou were
studied, and the following compounds were isolated
from n-butanol extracts, which were identified based
on their physicochemical as well as spectroscopic data
as luteolin (1), naringenin (2), puerarin (3), rutin (4),
quercetin (5), hesperetin (6), acacetin-7-O-α-L-rhamno-
pyranosyl (1–6)-β-D-glucopyranoside (7, flavonoids),
stigmasterol (8, steroid), ferulic acid (9, phenylpropa-
noid);, and colchicine (10, alkaloid). Among them, col-
chicine (10) was obtained from the plants for the first
time. All the isolated compounds were shown in
Figure 1.
Compound 1 (luteolin [20]), yellow crystal; m.p. 328–
330°C; molecular formula: C15H10O6; ESI-MS: m/z 287
[M+H]+, 309 [M+Na]+; 1H NMR (DMSO-d6,
500 MHz) δ: 7.43 (1 H, s, H-2′), 7.40 (1 H, d, J= 8.4 Hz,
H-6′), 6.89 (1 H, d, J= 8.4 Hz, H-5′), 6.68 (1 H, br, s, H-
8), 6.45 (1 H, s, H-3), 6.19 (1 H, br, s, H-6); 13C NMR
(DMSO-d6, 125 MHz) δ: 182.2 (C-4), 164.6 (C-7), 164.4
(C-3), 161.9 (C-9), 157.8 (C-5), 150.2 (C-4’), 146.2 (C-3’),
122.0 (C-1′), 119.5 (C-6’), 116.5 (C-5’), 113.8 (C-2’),
104.2 (C-2), 103.4 (C-10), 98.3 (C-8), 94.3 (C-6).
Compound 2 (naringenin [21]), yellow amorphous
crystal; m.p. 253–255°C; molecular formula: C15H12O5;
ESI-MS: m/z 271 [M-H]-; 1H NMR (CD3OD, 500 MHz)
δ: 7.28 (2 H, d, J= 8.4 Hz, H-20, 60), 6.79 (2 H, d,
J= 8.2 Hz, H-3′, 5′), 5.86 (1 H, d, J= 1.5 Hz, H-8), 5.31(1 H, d, J= 1.4 Hz, H-6), 3.12 (1 H, d, J= 0.9 Hz, H-2),
3.06 (1 H, brs, H-3a), 2.65 (1 H, brs, H-3b); 13C NMR
(CD3OD, 125 MHz) δ: 196.5 (C-4), 167.0 (C-7), 164.1
(C-5), 163.6 (C-9), 157.7 (C-4′), 129.7 (C-1′), 127.7 (C-20,
C-60), 114.9 (C-3/), 1 (C-5′), 102.0 (C-10), 95.7 (C-6), 94.8
(C-8), 79.1 (C-2), 42.7 (C-3).
Compound 3 (puerarin [22,23]), white crystal; m.p.
189–191°C; molecular formula: C21H20O9; ESI-MS: m/z
415 [M-H]-, 417 [M+H]+, 439 [M+Na]+, 455 [M+K]+;
1H NMR (CD3OD, 500 MHz) δ: 8.03 (1H, d, J= 9 Hz,
H-5), 6.98 (1 H, d, J= 9 Hz, H-6), 7.35 (2 H, d, J= 9 Hz,
H-2, 6), 6.83 (2 H, d, J= 9 Hz, H-3, 5), 8.16 (1 H, s, H-2),
5.09 (1 H, d, J= 10 Hz, H-1); 13C NMR (CD3OD,
125 MHz) δ: 176.9 (C-4), 161.7 (C-7, 9), 157.4 (C-40),
153.2 (C-2), 130.1 (C-20, 60), 126.8 (C-10, 5), 124.2 (C-3),
122.9 (C-10), 117.1 (C-30, C-50), 114.9 (C-6), 111.8 (C-8),
81.4 (C-500), 78.7 (C-300), 74.3 (C-100), 71.6 (C-400), 70.4
(C-200), 61.4 (C-600).
Compound 4 (rutin [24,25]), yellow crystal; m.p. 188–
190°C; molecular formula: C27H30O16; ESI-MS: m/z 609
[M-H]-, 633 [M+Na]+; 1H NMR (DMSO-d6,
500 MHz) δ: 7.56 (1 H, d, J = 2.0 Hz, H-20), 7.54 (1 H, d,
J = 2.0 Hz, H-60), 6.86 (1 H, d, J = 9.0 Hz, H-50), 6.39
(1 H, d, J = 1.9 Hz, H-30), 6.20 (1 H, d, J = 1.9 Hz, H-40),
5.36 (1 H, d, J = 7.3 Hz, H-100), 4.54 (1 H, d, J = 1.3 Hz,
1000-H); 13C NMR (DMSO-d6, 125 MHz) δ: 177.8 (C-4),
164.6 15 (C-7), 161.7 (C-5), 157.1 (C-9), 156.9 (C-2),
148.9 (C-40), 145.3 (C-30), 133.8 (C-3), 122.1 (C-10), 121.7
(C-60), 116.8 (C-50), 115.8 (C-20), 104.5 (C-10), 101.7 (C-
100), 101.3 (C-1000), 99.2 (C-6), 94.1 (C-8), 76.3 (C-300),
76.1 (C-500), 74.5 (C-200), 72.3 (C-4000), 71.0 (C-3000), 70.9
(C-2000), 70.5 (C-400), 68.8 (C-5000), 67.4 (C-600), 18.3 (C-
6000).
Compound 5 (quercetin [26]), yellow powder; m.p.
306–308°C; molecular formula: C15H10O7; ESI-MS: m/z
301 [M-H]-, 325 [M+Na]+, 341 [M+K]+; 1H NMR
(DMSO-d6, 500 MHz) δ: 7.64 (1 H, d, J= 2.3 Hz, H-2
/),
7.53 (1 H, dd, J= 8.6 Hz, J= 2.3 Hz, H-6/), 6.78 (1 H, d,
J= 8.6 Hz, H-5/), 6.28 (1 H, d, J= 2.3 Hz, H-8), 6.20 (1 H,
d, J= 1.8 Hz, H-6); 13C NMR (DMSO-d6, 125 MHz) δ:
176.4 (C-4), 164.4 (C-7), 161.2 (C-5), 156.7 (C-9), 148.2
(C-2), 147.3 (C-30), 145.6 (C-40), 136.3 (C-3), 122.5 (C-
10), 120.5 (C-60), 116.1 (C-50), 115.6 (C-20), 103.5 (C-10),
98.7 (C-6), 93.9 (C-8).
Compound 6 (hesperetin [27]), white powder; m.p.
216–218°C; molecular formula: C16H14O6; ESI-MS: m/z
301 [M-H]-, 303 [M+H]+, 325 [M+Na]+; 1 H NMR
(DMSO-d6, 6 500 MHz) δ: 6.91 (1 H, dd, J= 8.4, 2.4 Hz,
H-60), 6.90 (1 H, d, J= 2.4 Hz, H-20), 6.88 (1 H, d,
J= 8.4 Hz, H-50), 5.87 (1 H, d, J= 2.4 Hz, H-8), 5.86 (1 H,
d, J= 2.4 Hz, H-6), 5.38 (1 H, dd, J= 12.1, 2.8 Hz, H-2),
3.73 (s), 3.16 (1 H, dd, J= 17.2, 12.1 Hz, H-3b), 2.68
(1 H, dd, J= 17.2, 2.8 Hz, H-3a); 13C NMR (DMSO-d6,
125 MHz) δ: 196.7 (C-4), 167.2 (C-7), 164.0 (C-5), 163.3
Figure 1 Structures of compounds 1 to 10. These compounds were obtained from B. davidii and identified by spectroscopic and
physicochemical analysis.
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114.6 (C-60), 112.4 (C-30), 102.3 (C-10), 96.3 (C-6),
95.5 (C-8), 78.8 (C-2), 56.2 (C-70), 42.6 (C-3).
Compound 7 (acacetin-7-O-α-L-rhamnopyranosyl(1–
6)-β-D-glucopyranoside [28]), 14 yellow powder; m.p.
266–268°C; molecular formula: C28H32O14; ESI-MS: m/z
593 [M+H]+, 615 [M+Na]+, 631 [M+K]+; 1 H NMR
(DMSO-d6, 500 MHz) δ: 12.9 (1H, s, 16 OH-5), 8.05
(2 H, dd, J= 8.8 Hz, H-30, 50), 7.15 (2 H, dd, J= 8.8 Hz,
H-20, 60), 6.93 (1 H, S,H-3), 6.79 (1 H, d, J= 2.0 Hz, H-
8), 6.45 (1 H, d, J= 2.0 Hz, H-6), 5.07 (1 H, d, J= 7.2 Hz,
18 H-100), 4.55 (1 H, d, J= 1.6 Hz, H-1); 13C NMR
(DMSO-d6, 125 MHz) δ: 182.6 (C-4), 19 164.5 (C-2),
163.5 (C-7), 162.9 (C-5), 161.7 (C-40), 157.1 (C-9), 129.0(C-20), 128.5 20 (C-60), 123.2 (C-10), 115.3 (C-30), 115.3
(C-50), 105.9 (C-10), 104.4 (C-3), 101.0 (C-1000), 21 100.4
(C-100), 100.2 (C-6), 95.3 (C-8), 76.8 (C-300), 75.7 (C-500),
73.6 (C-200), 72.6 22 (C-4000), 71.3 (C-3000), 70.9 (C-2000),
68.4 (C-5000), 67.7 (C-400), 66.1 (C-600), 55.6 (OMe), 1 17.8
(C-6000).
Compound 8 (stigmasterol [20]), white powder; m.p.
166–168°C; molecular formula: C29H48O; ESI-MS: m/z
413 [M+H]+; 1H NMR (CDCl3, 500 MHz) δ: 5.34 (
1H,
br, s, 4 H-6), 5.14 (1 H, dd, J= 15.2 Hz, 8.8 Hz, H-22),
5.08 (1 H, dd, J= 15.2 Hz, 8.8 Hz, H-23), 3.49–3.53 (1 H,
m, H-3), 0.7–2.7 (43 H, m); 13C NMR (CDCl3,
125 MHz) δ: 140.8 (C-5), 138.4 (C-22), 129.3 (C-23),
121.8 (C-6), 71.9 (C-3), 56.9 (C-14), 56.0 (C-17), 51.3 (C-
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(C-12), 37.3 (C-1), 37.3 (C-10), 32.7 (C-7), 31.9 (C-8),
31.7 (C-25), 31.7 (C-2), 29.0 (C-16), 25.5 (C-28), 24.5 (C-
15), 21.3 (C-11), 21.3 (C-21), 21.3 (C-26), 19.5 (C-19),
19.1 (C-27), 12.4 (C-29), 12.1 (C-8).
Compound 9 (ferulic acid [29]), yellow crystal; m.p.
172–174°C; molecular formula: C10H10O4; ESI-MS: m/z
195 [M+H]+, 217 [M+Na]+; 1 H NMR (DMSO-d6,
500 MHz) δ: 3.89 (3 H, s, OCH3), 6.33 (1 H, d,
J= 16 Hz, H-8), 6.99 (1 H, d, J= 8.4 Hz, H-5), 7.11 (1 H,
14 dd, J= 8.4 Hz, H-6), 7.18 (1 H, d, H-2), 7.56 (1 H, d,
J= 16 Hz, H-7); 13C NMR 15 (DMSO-d6, 125 MHz) δ:
168.5 (C-1), 149.6 (C-30), 148.4 (C-4/), 145.1 (C-3), 126.3
(C-10), 123.4 (C-60), 116.1 (C-50), 116.0 (C-2), 111.6 (C-
20), 56.2 (−OCH3).
Compound 10 (colchicine [30]), yellow powder; m.p.
148–150°C; molecular formula: C22H25NO6; ESI-MS: m/
z 400 [M+H]+, 422 [M+Na]+, 438 [M+K]; 1H NMR
(CDCl3, 500 MHz) δ: 7.63 (1 H, s, H-8), 7.35 (1 H, d,
J= 10.9 Hz, H-12), 6.89 (1 H, d, J= 10.9 Hz, H-11), 6.55
(1 H, s, H-4), 4.65 (1 H, dt, H-7), 4.12 (3 H, s, OCH3-
10), 3.94 (3 H, s, OCH3-2), 3.91 (3 H, s, OCH3-3), 3.66
(3 H, s, OCH3-1), 2.38–2.01 (1 H, m, H-6);
13C NMR
(CDCl3, 125 MHz) δ: 179.6 (C-9), 170.2 (C-13), 164.1
(C-10), 153.6 (C-3), 152.6 (C-7a), 151.3 (C-1), 141.7 (C-
2), 137.0 (C-12a), 135.7 (C-12), 134.4 (C-4a), 130.5 (C-
8), 125.7 (C-12b), 113.0 (C-11), 107.4 (C-4), 61.7
(OCH3-1), 61.5 (OCH3 -2), 56.5 (OCH3-10), 56.2
(OCH3-3), 52.8 (C-7), 36.5 (C-6), 29.9 (C-5), 22.9 (C-14).
Anticancer activity
The potential effects of the extracts from B. davidii on
the viability of Mgc-803 and Bcap-37 cells were investi-
gated using MTT assay at 5 and 20 μM, with adriamycin
[31] used as the positive control [32,33]. MTT assay is a
common method of measuring cell proliferation. The
results summarized in Tables 1 and 2 show that luteolin
and colchicine possess potent activities against Mgc-803
cells. The activities of luteolin and colchicine at 72 h
after treatment were 13.2%± 4.2% and 26.2%±9.8%
against Mgc-803 cells, respectively. And inhibition rates
were 50.7%±7.4% and 42.3%±9.6% at 20 μM, respect-
ively. These results indicated that colchicine showed
more potent activity against Mgc-803 cells than that of
luteolin at 5 μM, but the reverse was true when the con-
centration was 20 μM. In addition, the results showed
that the inhibitory ratios of luteolin against Mgc-803
cells significantly changed compared with colchicine as
the concentration increased. Moreover, the synergistic
effect of luteolin and colchicine on the cancer cells were
also investigated. Unfortunately, the anticancer activity
was not obviously found by combination of luteolin and
colchicine. For instance, when the concentration was
5 μm, the anticancer activity against Mgc-803 cells were(27.9 ± 8.9)% at 72 h after treatment, whereas the con-
centration was 20 μm, the inhibitory ratios at 72 h after
treatment were (51.3 ± 2.4)% against Mgc-803 cells.
Further experiments also found that proliferation of
Mgc-803 cells was significantly 4 inhibited by luteolin
and colchicine, as shown in Figures 2 and 3. With
hydroxycamptothecine (HCPT) and etoposide (VP-16)
as positive controls, the IC50 values of luteolin and col-
chicine on Mgc-803 cells were 19.87±1.0 and 18.79
±1.6 μM, respectively, and IC50 values of luteolin and
colchicine on Bcap-37 cells were 41.78±2.2 and 76.01
±0.6 μM, respectively. The results also showed that
luteolin and colchicine had more potent activities against
Mgc-803 cells. Besides, the inhibitory effect on Bcap-37
cells of luteolin was stronger than that of colchicine.
Apoptosis is a physiological pattern of cell death char-
acterized by morphological features and extensive DNA
fragmentation, the frequency and time of appearance of
which depend on the cell line and the apoptosis-
inducing signal. It has been well studied that luteolin is
capable of inducing cell cycle arrest or apoptosis in vari-
ous human cancer cells [34-40], such as HT-29 human
colon cancer [34], hepatoma cells [35,36] , human mye-
loid leukaemia cells [37], human lung squamous carcin-
oma CH27 cell [38], and so on. Moreover, Colchicine
can induce cytoskeletal collapse and apoptosis in N-18
neuroblastoma [41] and showed Anti-Mitotic Activity
[42]. In order to preliminarily determine the action of
luteolin and colchicine, changes in the morphological
character of Mgc-803 cells were investigated using acrid-
ine orange (AO)/ethidium bromide (EB) staining,
Hoechst 33258 staining, and TUNEL (terminal deoxynu-
cleotidyl transferase biotin-dUTP nick end labeling)
staining under fluorescence microscopy to determine 3
whether the growth inhibitory activities of luteolin and
colchicine were related to the 4 induction of apoptosis.
Since AO is a crucial dye and can stain nuclear DNA
across an unbroken cell membrane, whereas EB can only
stain cells that had lost an intact cell membrane [43].
Thus, the following phenomena were observed after AO/
EB staining: (1) viable cells have been uniformly stained
green; (2) early apoptotic cells have been stained green 9
yellow or displayed green yellow fragments; (3) late apop-
totic cells have been stained orange or displayed orange
fragments; and (4) necrotic cells have been stained orange
to red fluorescing nuclei with no indication of chromatin
fragmentation. As shown in Figure 4, all the morpho-
logical changes were observed after Mgc-803 cells were
treated with luteolin and colchicine for 24, 36, and 48 h.
Green live Mgc-803 cells with a normal morphology were
seen in the negative control group (Figure 4A). In con-
trast, early apoptotic cells with yellow green dots and late
apoptotic cells with orange dots in Mgc-803 cell nuclei
could be seen in the positive control group (Figure 4B and
Table 1 Growth inhibitory effects of various constituents
of B. davidii on different cells at 5μM
Compound (5μM) Growth inhibition (%)
Mgc-803 Bcap-37
luteolin 13.2 ± 4.2 9.6 ± 6.8
naringenin 2.3 ± 2.9 5.3 ± 5.4
puerarin 0.4 ± 5.4 5.3 ± 7.6
rutin 8.3 ± 7.1 0.4 ± 3.7
quercetin 29.2 ± 4.1* 12.1 ± 8.2
hesperetin 0.0 ± 2.4 7.9 ± 6.4
acacetin-7-O-α-L- rhamnopyranosy
(1–6)- β-D-glucopyranoside
0.5 ± 4.3 0.9 ± 5.2
stigmasterol 0.8 ± 3.1 1.3 ± 7.4
ferulic acid 0.9 ± 6.0 8.2 ± 5.8
colchicine 26.2 ± 9.8* 19.4 ± 5.3*
Adriamycin 62.5 ± 4.6** 47.3 ± 5.5**
*P<0.05 and **P<0.01 versus control.
Table 2 Growth inhibitory effects of various constituents
of B. davidii on different cells at 20μM
Compound (20μM) Growth inhibition (%)
Mgc-803 Bcap-37
Luteolin 50.7 ± 7.4** 28.8 ± 3.0*
Naringenin 4.9 ± 3.0 12.0 ± 3.2
Puerarin 3.5 ± 7.0 11.1 ± 5.3
Rutin 21.0 ± 10.3* 7.3 ± 4.9
Quercetin 31.2 ± 6.2* 16.1 ± 6.8
Hesperetin 2.9 ± 4.8 10.6 ± 3.1
acacetin-7-O-α-L-rhamnopyr-anosy
(1–6)- β-D-glucopyranoside
4.2 ± 4.6 10.0 ± 4.0
stigmasterol 4.7 ± 5.1 2.6 ± 8.7
ferulic acid 3.9 ± 5.2 30.2 ± 5.8*
colchicine 42.3 ± 9.6** 26.5 ± 6.2*
Adriamycin 92.8 ± 1.0** 89.9 ± 1.3**
*P<0.05 and **P<0.01 versus control.
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with nuclear margination and chromatin coagulation were
seen in the experimental group (Figure 4D, G, J, K, M, and
19 N), as were orange late apoptotic cells with apoptotic
bodies and chromatin fragmentation (Figure 4E, F, H, I, L,
and O). The results suggested that both of colchicine and
luteolin were able to induce apoptosis in Bcap-37 cells.
Moreover, it can be seen that colchicine showed more
apoptotic activity against Mgc-803 cells than that of
luteolin.
Membrane-permeable Hoechst 33258 (a blue fluores-
cent dye with low cytotoxicity) staining was also per-
formed to investigate the apoptosis-inducing activities of
colchicine and luteolin in Mgc-803 cells. Live cells with
homogeneous light blue nuclei could be observed under
fluorescence microscopy after staining with Hoechst
33258, and the apoptotic cells displayed bright blue due to
karyopyknosis and chromatin condensation after treating
with Hoechst 33258, and the nuclei of dead cells could
not be stained [43]. As shown in Figure 5, all the men-
tioned changes could be observed. Compared with the
negative control (Figure 5A), a proportion of cells with
smaller nuclei and condensed staining appeared in the
positive control group (Figure 5B and C). Some Mgc-803
cells nuclei underwent pyknosis after treatment with col-
chicine for 24 and 36 h, as shown in Figure 5D–I, as did
some Mgc-803 cell nuclei after being treated with luteolin
for 24 and 36 h, as shown in Figure 5J–O. These results
confirmed that colchicine and luteolin could induce apop-
tosis in Mgc-803 cells and that colchicine had more potent
activity against Mgc-803 cells than luteolin.
TUNEL staining was further carried out to confirm
the cell apoptosis-inducing activities of colchicine and
luteolin. TUNEL staining is a common method fordetecting DNA fragmentation that results from apop-
totic signaling cascades [44]. Apoptotic cells thus show-
ing a brown color [43]. The experimental results are
demonstrated in Figure 6.
From the figure, it could be found that most nuclei in
the treatment groups with VP-16 (Figure 6B), HCPT
(Figure 6C), colchicine (Figure 6D), and luteolin
(Figure 6E) were stained as a discernible brown compared
with the control (Figure 6A).
Moreover, the apoptosis ratios induced by colchicine
and luteolin caused apoptosis in the Mgc-803 cells were
analyzed by flow cytometry with Annexin V/propidium
iodide (PI) double staining after treating with colchicine
and luteolin for 12, 24, and 36 h. Exposure of the mem-
brane phospholipid phosphatidylserine to the external
cellular environment is one of the earliest markers of
apoptotic cell death. Annexin V is a calcium-dependent
phospholipid-binding protein with high affinity for phos-
phatidylserine expressed on the cell surface used to dif-
ferentiate intact cells (Q3; Annexin V-/PI-). PI does not
penetrate whole cells with intact membranes and was
used to differentiate between necrotic cells (Q1; Annexin
V-/PI+), late apoptotic cells (Q2; Annexin V+/PI+), and
early apoptotic cells (Q4; Annexin V+/PI-). The results
are shown in Figure 7.
As indicated in Figure 7, the percentages of Q4
(Annexin V+/PI-) and Q2 (Annexin V+/PI+) were ap-
proximately 0.6% and 4.6% at 5 μM, 3.1% and 11.7% at
10 μM, and 15.0% and 44.4% at 20 μM, respectively after
12 h treating with luteolin. While the percentages that
were treated for 24 h were approximately 3.5% and
12.7% at 5 μM, 2.2% and 12.7% at 10 μM, and 3.3% and
45.1% at 20 μM for Q4 and Q2 cells, respectively. In
addition, the corresponding values of treating for 36 h
Figure 2 Effects of compounds on proliferation of Mgc-803 cells. After Mgc-803 cells were treated with HCPT, VP-16, luteolin, and colchicine
for 72 h in varying concentrations (1.25 to 20 μM), their growth inhibition was detected using MTT assay. Data are presented as mean±SD, n= 3.
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11.3% at 10 μM, and 15.4% and 43.7% at 20 μM, respect-
ively. When the experiments were treated with colchi-
cine, the percentages (after treating 12 h) of Q4 and Q2
cells were approximately 4.4% and 6.9% at 5 μM, 7.0%
and 12.9% at 10 μM, and 3.9% and 15.7% at 20 μM, re-
spectively. When the time was extended to 24 h, theFigure 3 Effects of compounds on proliferation of Bcap-37 cells. After
for 72 h in varying concentrations (1.25 to 20 μM), their growth inhibition wcorresponding percentages were approximately 2.8% and
12.8% at 5 μM, 7.7% and 13.0% at 10 μM, and 3.5% and
19.6% at 20 μM, respectively. Moreover, the correspond-
ing percentages (after treating for 36 h) were approxi-
mately 2.0% and 14.9% at 5 μM, 5.9% and 19.7% at
10 μM, and 7.7% and 35.2% at 20 μM, respectively.
These results showed that luteolin and colchicine mayBcap-37 cells were treated with HCPT, VP-16, luteolin, and colchicine
as detected using MTT assay. Data are presented as mean±SD, n= 3.
Figure 4 Morphological changes in the nuclei during luteolin- and colchicine-induced apoptosis in Mgc-803 cells detected by AO/EB
staining. After treatment with colchicine and luteolin at 5, 10, and 20 μM, Mgc-803 cells were stained with AO/EB (100 μg/μM) and observed under
fluorescence microscopy. A: Negative control (without treatment). B, C: Positive control; treatment with VP-16 and HCPT (20 μM) for 24 h, respectively.
D–F: Treatment with colchicine (5, 10, and 11 μM, respectively) for 24 h. G–I: Treatment with colchicine (5, 10, and μM, 12 respectively) for 36 h. J–L:
Treatment with luteolin (5, 10, and 20 μM, respectively) for 24 h. M–O: Treatment with luteolin (5, 10, and 20 μM, respectively) for 48 h.
Figure 5 Morphological changes in the nuclei during luteolin- and colchicine-induced apoptosis in Mgc-803 cells detected by Hoechst
33258 staining. After treatment with colchicine and luteolin at 5, 10, and 20 μM, Mgc-803 cells were stained with Hoechst 33258 and observed
under fluorescence microscopy. A: Negative control (without treatment). B, C: Positive control; treatment with VP-16 and HCPT (20 μM) for 48 h.
D–F: Treatment with colchicine (5, 10, and 20 μM, respectively) for 24 h. G–I: Treatment with colchicine (5, 10, and 20 μM, respectively) for 36 h.
J–L: Treatment with luteolin (5, 10, and 20 μM, respectively) for 24 h. M–O: Treatment with luteolin (5, 10, and 20 μM, respectively) for 48 h.
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Figure 6 Morphological changes during luteolin and colchicine-induced apoptosis in Mgc-803 cells detected by TUNEL staining. After
treatment with colchicine and luteolin at 20 μM, Mgc-803 cells were stained with TUNEL and observed under light microscopy. A: Negative
control (without treatment). B, C: Positive control; treatment with VP-16 and HCPT (20 μM) for 24 h. D: Treatment with colchicine (20 μM) for
24 h. E: Treatment with luteolin (20 μM) for 24 h.
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interference of cell proliferation via apoptosis in a dose-
and time-dependent manner.
In summary, the inhibitory effects observed in re-
sponse to colchicine and luteolin were associated with
the induction of apoptotic cell death.
Conclusions
B. davidii, a class of Chinese traditional medicine, which
showed variety of biologically activity and is widely dis-
tributed in southwestern of China. Studies on the chem-
ical constituents of B. davidii and their biological
activities have focused on the rational development and
utilization of this plant.
In the current study, 10 compounds were extracted
and identified from B. davidii grown in Guizhou, and
their cell growth inhibitory effects on Mgc-803 and
Bcap-37 cells were evaluated by MTT assay. Among
these ten compounds, colchicine 10 was extracted from
B. davidii firstly. Both of colchicines and luteolin showed
potent anticancer activities on Bcap-37 and BGC-823
cells in a dose-dependent manner. And the IC50 values
of luteolin and colchicine on Mgc-803 cells were 19.87
±1.0 and 18.79±1.6 μM, respectively, The IC50 values of
luteolin and colchicine on Bcap-37 cells were 41.78±2.2
and 76.01±0.6 μM, respectively. This is the first study to
have extracted colchicine from B. davidii. Moreover, the
apoptotic activities induced by colchicine and luteolin in
Mgc-803 cells were investigated through AO/EB stain-
ing, Hoechst 33258 staining, TUNEL assay, and flow
cytometry analysis. The results demonstrated that bothcompounds are promising adjuvant therapies for treating
human carcinoma cells. Further studies are needed to
clarify the action mechanism of B. davidii on the inhib-
ition of human malignant tumor cell proliferation.
Methods
Plant materials
Fresh B. davidii samples were collected from Bijie, Guiz-
hou, in 2008. The plant was identified by Professor Deq-
ing Long (Guiyang Medical University). A voucher
specimen was deposited in the Botany and Pharmacog-
nosy Department, School of Pharmacy, Guiyang Medical
University.
Extraction and isolation
Dried B. davidii (20 kg) samples were powdered and
extracted with ethanol at room temperature four times
for 7 days each. After filtration, the extract was evapo-
rated under reduced pressure for ethanol removal to ob-
tain a water suspension that was sequentially extracted
at room temperature with petroleum ether (5000 mL),
ethyl acetate (5000 mL), n-butanol (5000 mL), and water
(5000 mL).
The n-butanol extract of B. davidii (195 g) was chro-
matographed on a Si gel column (1800 g, 200–300
mesh) eluted with ethyl acetate/methanol mixtures. The
fractions eluted with a 10:1 ethyl acetate/methanol ratio
yielded 10.2 g of extract A, whereas those eluted with a
5:1 ethyl acetate/methanol ratio afforded 15.4 g of ex-
tract B. Extract A was subjected to passage over a Si gel
column (250 mL) and eluted with trichloromethane,
Figure 7 Flow cytometry analysis for apoptosis-inducing
activities of colchicine and luteolin in Mgc-803 cells. The
appearance of apoptosis cells was detected by flow cytometry using
Annexin V/PI staining. A–C: Negative control. D–I: Positive control;
treatment with HCPT and VP-16 (20 μM) for 12, 24, and 36 h. J–R:
Treatment with luteolin (5, 10, and 20 μM) for 12, 24, and 36 h. S–A:
Treatment with colchicine (5, 10, and 20 μM) for 12, 24, and 36 h.
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tionated into three parts (A1–A3): The A1 fraction was
purified on Merck Silica gel 60RP-18 (30%,40%, and 50%
methanol) to obtain compound 10 (18 mg) and com-
pound 8 (60 mg). The A2 fraction was purified on a
Sephadex LH-20 column (methanol/water) and then a Si
gel column (trichloromethane/methanol, 90:7) to obtain
compound 9 (43 mg). The A3 fraction was purified on
Si gel column (trichloromethane/methanol, 70:3) to ob-
tain compound 2 (30 mg).
Extract B was fractionated into four parts (B1–B4) over
a Si gel column (350 mL) eluting with trichloromethane/
methanol (30:1): The B1 fraction was purified on Merck
Silica gel 60RP-18 (30%, 40%, 50%, and 100% methanol) to
obtain compound 6 (25 17 mg) and compound 5 (63 mg).
The B2 fraction was purified on Merck Silica gel 18 60RP-
18 (40%, 50%, and 100% methanol) to obtain compound 3
(31 mg) and compound 1 (24 mg). The B3 fraction was
purified on a Si gel column (trichloromethane/methanol,
10:7) to obtain compound 7 (160 mg). The B4 fraction
was purified on a Sephadex LH-20 column (methanol) to
obtain compound 4 (42 mg).Cell lines and culture
The human gastric cancer cell line Mgc-803, human breast
cancer cell line Bcap-37 were grown in RPMI (Roswell Park
Memorial Institute) 1640 and supplemented with 10% fetal
bovine serum at 37°C in a humidified atmosphere with 5%
CO2; All cell lines were purchased from Institute of Bio-
chemistry and Cell Biology, Shanghai Institute for Biological
Sciences, Chinese Academy of Sciences.Anticancer activity assays
MTT assay
The activities of the compounds in Mgc-803, Bcap-37
were evaluated in vitro using MTT assay. All cell lines
(2000 cells/well) were incubated for 24 h at 37°C in an
atmosphere of 5% CO2 before the compounds were
added. After treatment with various concentrations of
each extract, the cells were incubated for an additional
72 h at 37°C in 5% CO2. Subsequently, the medium was
removed and the cells in each well were incubated with
100 μL of MTT solution (0.5 mg/mL) for 4 h at 37°C. Fi-
nally, the mixture was supplemented with sodium dode-
cyl sulfate and the cells were incubated for 12 h at 37°C.
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hibition rate was calculated as follows:





Apoptotic morphology was investigated by double stain-
ing with AO and EB as described by Baskic et al. [45]. In
the experiment, Mgc-803 cells were seeded in six-well
plates at 5 × 104 cells per well in 0.8 mL of RPMI 1640
medium supplemented with 10% fetal bovine serum and
cultured for 24 h, followed by removal of the culture
medium, replacement with fresh medium plus 10% fetal
bovine serum, and supplementation with puerarin and
colchicine. After the treatment period, the cover slips
with monolayer cells were inverted on a glass slide with
20 μL of AO/EB stain (100 μg/mL). Fluorescence was
read on an IX71SIF-3 fluorescence microscope (OLYM-
PUS Co., Japan).
Hoechst 33258 staining
Mgc-803 cells grown on sterile cover slips in six-well tis-
sue culture plates were treated with puerarin and colchi-
cine for a certain range of time. The culture medium
containing compounds was removed, and the cells were
fixed with 4% paraformaldehyde for 10 min. After wash-
ing twice with PBS, the cells were stained with 5 μg/mL
of Hoechst 33258 for 5 min. After rewashing twice with
PBS, the percentage of apoptotic cells was determined
using an IX71SIF-3 fluorescence microscope. As some
of the dead cells were rinsed off as the experiment pro-
gressed, the apoptotic ratios could have been underesti-
mated in comparison with those from the MTT assay.
TUNEL staining
TUNEL assay identifies apoptosis by tagging the 3’-OH
ends of DNA fragments with fluorescein [41]. In the
present study, Mgc-803 cells grown in six-well tissue
culture plates were treated with puerarin and colchicine.
The cells were subsequently washed once in 1 mL of
PBS and fixed in 4% paraformaldehyde for 60 min. After
another round of washing with PBS, the cells were incu-
bated with Immunol staining wash buffer (Beyotime) on
ice for 2 min. Cells were rewashed once with PBS and
then incubated in 0.3% H2O2 in methanol at room
temperature for 20 min to inactivate the endogenous
peroxidases, after which the cells were washed three
times with PBS. Thereafter, the cells were incubated with
2 μL of terminal deoxynucleotidyl transferase enzyme
and 48 μL of biotin-dUTP per specimen for 60 min at
37°C. After termination for 10 min, the cells wereincubated with 50 μL of streptavidin-HRP for 30 min at
room temperature after being washed thrice with PBS.
Flow cytometry analysis
For measuring apoptosis, Mgc-803 cells were seeded in
six-well plates at a density of 5 × 105 cells/mL for 24 h
and then treated with puerarin and colchicine at 5, 10,
and 20 μM. After 12, 24, or 36 h, the cells were col-
lected, washed twice with PBS, and centrifuged at room
temperature. Subsequently, the Mgc-803 cells were gen-
tly resuspended in 500 μL of binding buffer. Thereafter,
the cells were stained in 5 μL of Annexin V/FITC and
shaken well. Finally, 5 μL of PI was added to these cells;
the reaction was incubated for 40 min in the dark and
analyzed using FACSCalibur (Becton Dickinson).
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